Atossa Therapeutics, Inc.
ATOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $119 | $111 | $67 | $187 |
| - Cash | $71 | $88 | $111 | $136 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $48 | $22 | -$44 | $51 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$28 | -$31 | -$28 | -$20 |
| % Margin | – | – | – | – |
| Net Income | -$26 | -$30 | -$27 | -$21 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.2 | -0.24 | -0.21 | -0.18 |
| % Growth | 16.7% | -14.3% | -16.7% | – |
| Operating Cash Flow | -$21 | -$21 | -$21 | -$16 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$21 | -$21 | -$21 | -$16 |